Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV), today released financial results for the first quarter ended March 31, 2007. First quarter revenues were $59.3 million with net income and earnings per fully diluted share of $36.4 million and $1.03, respectively. Unless otherwise specified, all amounts are in U.S. dollars and are reported under U.S. GAAP.

“In the first quarter, we made meaningful progress in our two clinical programs, including the milestone of last patient last dose which we reached in March for the induction phase of our lupus nephritis trial. We look forward to receiving the preliminary results of this study evaluating the use of CellCept in the treatment of this disease,” said Richard M. Glickman, Chairman and Chief Executive Officer of Aspreva.

Mr. Glickman added, “As we head into the second quarter, the strength of our balance sheet and the depth of our clinical, regulatory, and commercialization skills, leave us well-positioned for the next phase of our growth as a pharmaceutical company.”